WHO discontinues two pain management guidelines

27th June 2019

WHO is discontinuing the following two guidelines in light of new scientific evidence that has emerged since the time of their publication and to address issues of conflicts of interest of the experts that have been raised:

• Ensuring balance in national policies on controlled substances: Guidance for availability and accessibility of controlled medicines (2011)
• WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses (2012).

Click here to view

click here to view

WHO guidelines for treatment of cancer pain published

18th June 2019

The World Health Organisation has published ‘Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents.

Click here to view

click here to view

Epistatus 10mg oromucosal solution SPC updated

4th June 2019

Information has been added to the SPC regarding the risk of use of Epistatus (midazolam) 10mg oromucosal solution in hepatic impairment: Because hepatic impairment reduces the clearance of midazolam and increases the terminal half-life, the clinical effects may be stronger and prolonged. Note. Epistatus is contra-indicated in patients with severe hepatic impairment. Warnings have also been added regarding the increased risk of CNS depression if using opioids concurrently.

Click here to view

click here to view